Erick Lucera insider trades
Open-market stock purchases and sales by Erick Lucera, Chief Financial Officer at Dyne Therapeutics, Inc, from SEC Form 4 filings since Mar 23, 2017.
Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -66%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Aug 13, 2026 | DYN Dyne Therapeutics, Inc | Sold | $47.2K |
| Jun 25, 2026 | DYN Dyne Therapeutics, Inc | Sold | $48.1K |
| May 13, 2026 | DYN Dyne Therapeutics, Inc | Sold | $26.6K |
| Apr 1, 2026 | DYN Dyne Therapeutics, Inc | Sold | $107K |
| Feb 12, 2026 | DYN Dyne Therapeutics, Inc | Bought (not open market) | — |
| Feb 12, 2026 | DYN Dyne Therapeutics, Inc | Bought (not open market) | — |
| Dec 16, 2025 | SABS SAB Biotherapeutics, Inc | Bought (not open market) | — |
| Nov 4, 2025 | XAIR Beyond Air, Inc | Bought (not open market) | $1.9K |
| Nov 4, 2025 | XAIR Beyond Air, Inc | Sold (not open market) | $10.8K |
| Nov 4, 2025 | XAIR Beyond Air, Inc | Sold (not open market) | $13.5K |
| Nov 4, 2025 | XAIR Beyond Air, Inc | Bought (not open market) | $2.4K |
| Nov 4, 2025 | XAIR Beyond Air, Inc | Sold (not open market) | $22.1K |
| Nov 4, 2025 | XAIR Beyond Air, Inc | Bought (not open market) | $7.3K |
| Nov 4, 2025 | XAIR Beyond Air, Inc | Sold (not open market) | $24.3K |
| Nov 4, 2025 | XAIR Beyond Air, Inc | Bought (not open market) | $4.4K |
| Nov 4, 2025 | XAIR Beyond Air, Inc | Sold (not open market) | $21.6K |
| Nov 4, 2025 | XAIR Beyond Air, Inc | Bought (not open market) | $3.9K |
| Nov 4, 2025 | XAIR Beyond Air, Inc | Sold (not open market) | $16.2K |
| Nov 4, 2025 | XAIR Beyond Air, Inc | Bought (not open market) | $2.9K |
Companies traded
- DYN Dyne Therapeutics, Inc: 4 sales, last Aug 13, 2026
- SABS SAB Biotherapeutics, Inc: other filings, last Dec 16, 2025
- XAIR Beyond Air, Inc: 2 buys, last Nov 4, 2025
- EDIT Editas Medicine, Inc: 2 sales, last Mar 8, 2025
- BBLG Bone Biologics Corp: other filings, last Sep 18, 2023
- AVEO Aveo Pharmaceuticals, Inc: other filings, last Jan 19, 2023
- VLRX Valeritas Holdings Inc: 3 buys, last Nov 19, 2018
- AITB AIT Therapeutics, Inc: 1 buy, last Aug 13, 2018